Search results
Our Keynote speaker will be Mr Kanmin Xue. Mr Xue is a Consultant Vitreo-retinal Surgeon at the John Radcliffe Hospital and Wellcome Trust clinician scientist fellow at the University of Oxford where he leads the Retinal Disease and Repair Group.
A discovery made as part of research funded by Retina UK has led to a prestigious award of $2.5 million, enabling scientists to undertake more in-depth investigations and work towards a treatment for a particular type of retinitis pigmentosa.
Stem cells are a special type of cell, which under the right conditions can be encouraged to grow into any other type of cell in the body, including retinal cells (rods, cones and retinal pigment epithelial cells).
Growth factors are substances that promote the health and function of cells and tissues in the body.
ProQR has published the top-line results from its Phase 2/3 “Illuminate” trial of the RNA therapy sepofarsen for Leber congenital amaurosis type 10 caused by a specific mutation in the CEP290 gene.
In 2014 we funded an exciting new collaborative project. The UK Inherited Retinal Dystrophy Consortium (UKIRDC) Project brought together the four largest research groups in the UK specialising in inherited retinal diseases (IRDs).
The Spring 2023 edition of the Retina UK newsletter, Look Forward, which includes articles about our upcoming events, research updates and more.
Our Medical Advisory Board (MAB) advises our Board of Trustees in order that they can approve grants for research projects.
Thank you to all those who completed our recent Sight Loss Survey – almost 700 of you took the time to share your experiences.
Inflammation and retinal degeneration in retinitis pigmentosa: Can lessons learned in the lab help us identify treatments in the clinic?
